932750-29-3

Basic information

• Product Name: Ethyl (E)-2-cyano-3-ethoxycrotonate
• Synonyms: Ethyl (E)-2-cyano-3-ethoxycrotonate;(E)-ethyl 2-cyano-3-ethoxybut-2-enoate
• CAS NO: 932750-29-3
• Molecular Formula: C9H13NO3
• Molecular Weight: 183.2
• Mol File: 932750-29-3.mol
• Article Data: 21

Chemical Properties

• Melting Point: 71-73°
• Boiling Point: 304.6°C at 760 mmHg
• Flash Point: 132°C
• Appearance: /
• Density: 1.055g/cm³
• Vapor Pressure: 0.000863mmHg at 25°C
• Refractive Index: 1.453
• CAS DataBase Reference: Ethyl (E)-2-cyano-3-ethoxycrotonate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl (E)-2-cyano-3-ethoxycrotonate(932750-29-3)
• EPA Substance Registry System: Ethyl (E)-2-cyano-3-ethoxycrotonate(932750-29-3)

Safety Data

• RIDADR: UN3439/PG:III/Hazard Class:6.1
• HazardClass: 6.1
• PackingGroup: III
• Hazardous Substances Data: 932750-29-3(Hazardous Substances Data)

Usage

General Description

Ethyl (E)-2-cyano-3-ethoxycrotonate is a chemical compound with the molecular formula C9H11NO3. It is commonly used as an intermediate in the synthesis of various pharmaceuticals and agrochemicals. Ethyl (E)-2-cyano-3-ethoxycrotonate is known for its role as a key building block in the assembly of complex organic molecules. Additionally, it is used in the development of new drugs and as a precursor in the production of insecticides and herbicides. Its unique chemical structure and reactivity make it an important component in the field of organic chemistry and drug discovery.

InChI:InChI=1/C9H13NO3/c1-4-12-7(3)8(6-10)9(11)13-5-2/h4-5H2,1-3H3/b8-7+

Upstream product

• 78-39-7 Triethyl orthoacetate 
• 105-56-6 ethyl 2-cyanoacetate 
• 186581-53-3 diazomethane 
• 94-05-3 ethyl (ethoxymethylene)cyanoacetate 
• 75-03-6 ethyl iodide 

Downstream Products

• 86474-52-4 ethyl (Z)-2-cyano-3-(2-methoxyanilino)but-2-enoate 
• 86474-50-2 Ethyl 3-N-o-chloroanilino-2-cyanocrotonate 
• 84095-95-4 5-Amino-1-benzylsulfanylthiocarbonyl-3-methyl-1H-pyrazole-4-carboxylic acid ethyl ester 
• 34605-62-4 ethyl 5-amino-1,3-dimethyl-1H-pyrazole-4-carboxylate 
• 288249-59-2 N-(3-cyano-4-isobutylphenyl)-1-(4-fluorophenyl)-3-methylpyrazole-4-carboxamide 
• 288251-57-0 1-(2,4-difluorophenyl)-3-methylpyrazole-4-carboxylic acid 
• 288251-55-8 ethyl 1-(4-fluorophenyl)-3-methylpyrazole-4-carboxylate 
• 288250-02-2 N-(3-cyano-4-(4-tert-butyldimethylsilyloxypiperidin-1-yl)phenyl)-1-(4-fluorophenyl)-3-methylpyrazole-4-carboxamide 
• 288250-03-3 N-[3-cyano-4-(4-hydroxypiperidin-1-yl)phenyl]-N-[1-(4-fluorophenyl)-3-methylpyrazol-4-ylcarbonyl]glycine 
• 288250-06-6 N-[3-cyano-4-neopentyloxypheny]-N-[1-(2,4-difluorophenyl)-3-methylpyrazol-4-ylcarbonyl]glycine 
• 1418313-48-0 ethyl N-(3-cyano-4-neopentyloxyphenyl)-N-[1-(4-fluorophenyl)-5-methylpyrazol-4-ylcarbonyl]glycine 
• 288249-69-4 N-(3-cyano-4-neopentyloxyphenyl)-N-[1-(4-fluorophenyl)-5-methylpyrazol-4-ylcarbonyl]glycine 
• 288249-49-0 N-(3-cyano-4-neopentyloxyphenyl)-N-[1-(4-fluorophenyl)-3-methylpyrazol-4-ylcarbonyl]glycine 
• 288249-85-4 N-[3-cyano-4-(4-hydroxypiperidin-1-yl)phenyl]-1-(4-fluorophenyl)-3-methylpyrazole-4-carboxamide 

Relevant articles and documents

Aromatic ring dioxane quinazoline or quinoline compound, composition and application of aromatic ring dioxane quinazoline or quinoline compound

The invention relates to a novel compound serving as an inhibitor of kinase such as TRK, c-MET, AXL, MER and/or VEGFR2, a composition and application of the novel compound. Specifically, the inventionprovides a compound (as shown in formula (1)) or an isomer, a solvate, a hydrate, a pharmaceutically acceptable salt and a prodrug thereof, and a pharmaceutical composition containing the compound, wherein the compound has the activity of strongly inhibiting kinase such as TRK, c-MET, AXL, MER and/or VEGFR2. The invention further discloses application of the compound or the pharmaceutical composition in preparation of a medicine. The medicine is used for treating autoimmune diseases or cancers.

SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS NADPH OXIDASE INHIBITORS

The present application relates to substituted fused heteroaryl and heterocyclic compounds, useful as nicotinamide adenine dinucleotide phosphate oxidase inhibitors (NADPH oxidase inhibitors), processes for their preparation, pharmaceutical compositions comprising the compounds, and the use of the compounds or the compositions in the treatment or prevention of various diseases, conditions and/or disorders mediated by NADPH oxidase. (Formula I)

COMPOUNDS USEFUL FOR ALTERING THE LEVELS OF BILE ACIDS FOR THE TREATMENT OF DIABETES AND CARDIOMETABOLIC DISEASE

Described herein are compounds of Formula (I) or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as Cyp8b1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for diabetes and cardiovascular disease.